Core Viewpoint - The announcement indicates that the SYS6055 injection developed by the company has received approval from the National Medical Products Administration (NMPA) of China to conduct clinical trials, marking it as the first domestically approved in vivo CAR-T product for clinical use [1]. Group 1: Product Details - SYS6055 is designed to generate CAR-T cells targeting CD19 directly in vivo using a lentiviral vector, which allows for specific recognition and elimination of target cells [1]. - Compared to traditional CAR-T products, SYS6055 has potential advantages in terms of cost, accessibility, and immediacy [1]. - Preclinical studies have shown that SYS6055 can specifically generate CAR-T cells in vivo, demonstrating significant anti-tumor effects and good safety profiles [1]. Group 2: Clinical Applications - The approved clinical indication for SYS6055 is for the treatment of relapsed/refractory aggressive B-cell lymphoma [1]. - The product also has potential applications for treating other CD19-positive B-cell malignancies and autoimmune diseases, indicating high clinical development value [1].
石药集团(01093.HK)：SYS 6055注射液在中国获临床试验批准